Skip to content
DataLookout
Menu

NCT05397496

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 40 versions: 39 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Primary and study completion pushed from Jan 4, 2027 to May 31, 2027
    • Secondary endpoints: details revised at 6 of 12 entries
    • Site details revised at 1 of 18 sites
  2. Minor Primary and study completion pushed from Aug 20, 2026 to Jan 4, 2027v39
  3. Minor Primary and study completion pushed from Jul 16, 2026 to Aug 20, 2026v38
  4. Minor Primary and study completion pushed from May 14, 2026 to Jul 16, 2026
    • Site details revised at 1 of 18 sites
    v37
  5. Notable Primary and study completion dates moved earlier to May 14, 2026v36
Show 33 earlier versionsHide 33 earlier versions
  1. Minor Enrollment target: estimated 140 to confirmed 61
    • Study sites: 19 to 18
    v35
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 21 to 19
    v34
  3. Minor Study sites: 20 to 21v33
  4. Minor Study sites: 19 to 20v32
  5. Minor Study sites: 18 to 19v31
  6. Minor Study sites: 17 to 18v30
  7. Minor Study sites: 16 to 17v29
  8. Minor Study sites: 15 to 16v28
  9. Minor Study sites: 16 to 15v27
  10. Minor Study sites: 15 to 16v26
  11. Minor Study sites: 14 to 15v25
  12. Minor Site details revised at 3 of 14 sitesv24
  13. Notable Eligibility criteria shortened, about 6 words
    • Study sites: 11 to 14
    • Study description shortened, about 22 words
    v23
  14. Minor Study sites: 13 to 11v22
  15. Minor Study sites: 12 to 13v21
  16. Minor Site details revised at 2 of 12 sitesv20
  17. Minor Study sites: 11 to 12v19
  18. Notable Primary completion date: Feb 28, 2025 to Jun 7, 2027
    • Study completion date: Feb 27, 2026 to Jun 5, 2028
    v18
  19. Minor Study sites: 10 to 11v17
  20. Minor Study sites: 9 to 10v16
  21. Minor Study sites: 8 to 9v15
  22. Minor Study sites: 7 to 8v14
  23. Minor Study sites: 6 to 7v13
  24. Minor Study sites: 5 to 6v12
  25. Notable Primary completion date: Aug 22, 2024 to Feb 28, 2025
    • Study completion date: Aug 21, 2025 to Feb 27, 2026
    v11
  26. Minor Study sites: 4 to 5v10
  27. Minor Study sites: 2 to 4
    • Primary completion date: Jun 13, 2024 to Aug 22, 2024
    v9
  28. Minor Study completion date: Jun 12, 2025 to Aug 21, 2025v8
  29. Minor Start date changed from estimate of Oct 24, 2022 to Oct 3, 2022v6
  30. Notable Start date: Sep 12, 2022 to Oct 24, 2022v5
  31. Minor Study sites: 1 to 2v4
  32. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Jun 3, 2024 to Jun 13, 2024
    • Study completion date: Jun 2, 2025 to Jun 12, 2025
    • Start date: Aug 31, 2022 to Sep 12, 2022
  33. Notable Start date: Jul 29, 2022 to Aug 31, 2022
    • Primary completion date: May 1, 2024 to Jun 3, 2024
    • Study completion date: Apr 30, 2025 to Jun 2, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and severity of Dose Limiting Toxicities (DLTs)
Timeframe: 28 days or 35 days, depending on the dosing schedule
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 21 months
Frequency of dose interruptions
Timeframe: 21 months
Frequency of dose reductions
Timeframe: 21 months
Dose intensities
Timeframe: 21 months

Secondary (12)

Overall Response Rate (ORR)
Complete Response (CR) rate
Best Overall Response (BOR)
Duration Of Response (DOR)
Overall Survival (OS)
Show 7 moreShow less
Progression Free Survival (PFS)
Event-free survival (EFS)
Maximum concentration of PIT565 (Cmax)
Area Under the Curve of PIT565 (AUC)
Trough concentration of PIT565 (C trough)
Prevalence of Anti-drug antibodies (ADA) at baseline
Incidence of Anti-drug antibodies (ADA) on treatment

Arms and interventions

PIT565 Group A (dose escalation part)Experimental

PIT565 in adult NHL patients for whom two or more lines of chemotherapy have failed and either having progressed (or relapsed) after autologous hematopoietic stem cell transplantation (HSCT), or being ineligible for or not consenting to the procedure

PIT565 Group B (dose escalation part)Experimental

PIT565 in adult R/R ALL patients.

PIT565 Group A1 (dose expansion part)Experimental

PIT565 Recommended dose 1 (RD1) in adult R/R large B-cell lymphoma (LBCL) (DLBCL, double/triple hit High-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL), Follicular lymphoma grade 3B (FL3B)) patients.

PIT565 Group A2 (dose expansion part)Experimental

PIT565 RD2 in adult R/R LBCL (DLBCL, double/triple hit HGBCL, PMBCL, FL3B) patients.

PIT565 Group B1 (dose expansion part)Experimental

PIT565 in adult R/R ALL patients.

Biologicals: PIT565

Sites

18 sites in 9 countries

United States 5, China 3, France 2, Singapore 2, Spain 2, Belgium 1, Israel 1, Italy 1, Japan 1